Bruce N. Jacobs Kymera Therapeutics, Inc. (KYMR) insider trading activity

Bruce N. Jacobs is Chief Financial Officer of Kymera Therapeutics, Inc.. Currently has a direct ownership of 168,554 shares of KYMR, which is worth approximately $7.33 Million. The most recent transaction as insider was on Jun 27, 2024, when has been sold 25,000 shares (Common Stock) at a price of $2.08 per share, resulting in proceeds of $52,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 169K

18.41% 3M change

46.52% 12M change

Total Value Held $7.33 Million

Bruce N. Jacobs Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 27 2024	BUY Exercise of conversion of derivative security	$52,000 $2.08 p/Share	25,000 Added 12.92%	168,554 Common Stock
Mar 04 2024	SELL Open market or private sale	$166,604 $42.35 p/Share	3,934 Reduced 2.69%	142,351 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	31,250 Added 17.6%	146,285 Common Stock
Jun 02 2023	BUY Exercise of conversion of derivative security	$20,800 $2.08 p/Share	10,000 Added 8.0%	115,035 Common Stock
Mar 02 2023	SELL Open market or private sale	$42,661 $31.14 p/Share	1,370 Reduced 1.29%	104,568 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	23,750 Added 18.31%	105,938 Common Stock
Oct 21 2022	BUY Exercise of conversion of derivative security	$20,800 $2.08 p/Share	10,000 Added 10.96%	81,279 Common Stock

Oct 17 2022	BUY Exercise of conversion of derivative security	$20,800 $2.08 p/Share	10,000 Added 12.3%	71,279 Common Stock
May 03 2022	BUY Exercise of conversion of derivative security	$41,600 $2.08 p/Share	20,000 Added 24.75%	60,814 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	13,300 Added 24.58%	40,814 Common Stock
Jan 14 2022	BUY Exercise of conversion of derivative security	$20,800 $2.08 p/Share	10,000 Added 26.66%	27,514 Common Stock
Jan 12 2022	SELL Open market or private sale	$783,000 $52.2 p/Share	15,000 Reduced 46.13%	17,514 Common Stock
Jan 12 2022	BUY Exercise of conversion of derivative security	$31,200 $2.08 p/Share	15,000 Added 31.57%	32,514 Common Stock
Dec 03 2021	SELL Open market or private sale	$542,300 $54.23 p/Share	10,000 Reduced 36.35%	17,514 Common Stock
Dec 03 2021	BUY Exercise of conversion of derivative security	$20,800 $2.08 p/Share	10,000 Added 26.66%	27,514 Common Stock
Nov 23 2021	BUY Exercise of conversion of derivative security	$20,800 $2.08 p/Share	10,000 Added 36.69%	17,256 Common Stock
Sep 03 2021	SELL Open market or private sale	$602,800 $60.28 p/Share	10,000 Reduced 57.95%	7,256 Common Stock
Sep 03 2021	SELL Exercise of conversion of derivative security	$20,800 $2.08 p/Share	10,000 Reduced 36.69%	17,256 Common Stock
Jun 03 2021	SELL Open market or private sale	$469,000 $46.9 p/Share	10,000 Reduced 57.95%	7,256 Common Stock
Jun 03 2021	BUY Exercise of conversion of derivative security	$20,800 $2.08 p/Share	10,000 Added 36.69%	17,256 Common Stock
Apr 13 2021	BUY Exercise of conversion of derivative security	$14,560 $2.08 p/Share	7,000 Added 50.0%	7,000 Common Stock
Mar 15 2021	SELL Open market or private sale	$493,093 $60.17 p/Share	8,195 Reduced 100.0%	0 Common Stock
Mar 15 2021	BUY Exercise of conversion of derivative security	$17,046 $2.08 p/Share	8,195 Added 50.0%	8,195 Common Stock
Mar 11 2021	SELL Open market or private sale	$108,426 $60.07 p/Share	1,805 Reduced 100.0%	0 Common Stock
Mar 11 2021	BUY Exercise of conversion of derivative security	$3,754 $2.08 p/Share	1,805 Added 50.0%	1,805 Common Stock

BNJ

Bruce N. Jacobs

Chief Financial Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KYMR shares.

Notify only if

Value

Insider Trading

Get notified when an Kymera Therapeutics, Inc. insider buys or sells KYMR shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kymera Therapeutics, Inc.

Track Activities on KYMR

Account